Monitoring osteoporosis therapy with bone densitometry: Misleading changes and regression to the mean

JAMA

Volumn 283, Issue 10, 2000, Pages 1318-1321

  Cummings, Steven R ^a,e   Palermo, Lisa ^a   Browner, Warren ^a   Marcus, Robert ^b   Wallace, Robert ^c   Pearson, Jim ^a   Blackwell, Terri ^a   Eckert, Stephen ^d   Black, Dennis ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA PALO ALTO HEALTH CARE SYSTEM   (United States)

^c UNIVERSITY OF IOWA   (United States)

^d ELI LILLY AND COMPANY   (United States)

^e NONE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; RALOXIFENE;

ADULT; AGED; ARTICLE; BONE DENSITY; BONE MINERAL; CLINICAL PRACTICE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DENSITOMETRY; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MONITORING; FEMALE; HUMAN; MAJOR CLINICAL STUDY; OSTEOPOROSIS; OUTCOMES RESEARCH; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; REGRESSION ANALYSIS; RISK BENEFIT ANALYSIS;

EID: 0034008503     PISSN: 00987484     EISSN: None     Source Type: Journal    
DOI: 10.1001/jama.283.10.1318     Document Type: Article

References (10)

1. Gardner MJ, Hardy JA. Some effects of within-person variability in epidemiological studies. J Chronic Dis. 1973;26:781-795.
2. Black DM, Cummings SR, Karpf DB, et al. Randomized trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet. 1996;348:1535-1541.
3. Cummings SR, Black DM, Thompson DE, et al. Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures. JAMA. 1998;280:2077-2082.
4. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene [published correction appears in JAMA. 1999;282:2124]. JAMA. 1999;282:637-644.
5. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene [published correction appears in JAMA. 1999;282:2124]. JAMA. 1999;282:637-644.
6. Yudkin PL, Stratton JM, How to deal with regression to the mean in intervention studies. Lancet. 1988; 347:241-243.
7. Grampf S, Genant HK, Mathur A, et al. Comparisons of noninvasive bone mineral measurements in assessing age-related loss, fracture discrimination, and diagnostic classification. J Bone Miner Res. 1997;12:697-711.
8. Sebastian-Gambaro MA, Liron-Hernandez FJ, Fuentes-Arderlu X. Intra- and inter-individual biological variability data bank. Eur J Clin Chem Clin Biochem. 1997;35:845-852.
9. Machado ABDC, Hannon R, Eastell R. Monitoring alendronate therapy for osteoporosis. J Bone Miner Res. 1999;14:602-608.
10. Looker A, Bauer D, Chestnut C, et al. Clinical use of markers of bone remodeling: current status and future directions. J Bone Miner Res. In press.